Clinical Studies and U.S. Tax Presence

Clinical investigations are often treated as a regulatory and operational phase rather than a commercial one. For tax purposes, however, a foreign sponsor or manufacturer may conduct meaningful U.S. activity before product approval or general launch. The relevant questions are what occurs, who performs it, where assets are located, and which entity controls the work.

Study Sites Do Not Automatically Create Tax Presence

An independent hospital, clinic or investigator ordinarily performs services under a study agreement rather than operating as the sponsor’s office. That distinction is important but not conclusive. Tax advisers may need to examine whether the foreign company has dedicated space, controls site personnel, conducts business through the location, or gives local personnel authority to bind it. Treaty protection, where available, depends on the applicable permanent-establishment provisions and facts.

Monitors and Other Personnel Can Change the Analysis

Clinical research associates, field specialists, trainers, technical personnel and sponsor employees may spend substantial time at study sites or work from U.S. homes. Their presence, responsibilities, reporting lines and authority should be reviewed. Using a contract research organization, consultant or staffing provider does not eliminate exposure if personnel are closely directed, perform core functions, or exercise authority for the foreign company.

Inventory and Logistics Require Separate Review

Investigational devices, replacement units, accessories and study supplies may be held at a depot, investigator site, laboratory or service provider. Ownership, title, control, replenishment, return rights and purpose can affect state income-tax nexus and apportionment.

Public Law 86-272 is generally a poor fit for study activity involving research, training, monitoring, technical support and other services.

Reimbursed Investigational Devices Require Additional Review

Where the Centers for Medicare & Medicaid Services has approved reimbursement of the investigational device, the study may include a device-sale and reimbursement cycle rather than solely sponsor-funded research. The parties should identify who invoices the site, receives payment, holds the receivable, and bears denied-claim, return, replacement or nonpayment risk.

CMS coverage does not itself create tax presence, but repeated supplies of reimbursable devices to U.S. providers may affect federal income-tax analysis, state nexus and apportionment, sales-and-use-tax obligations, and transfer pricing. The charging model must also remain consistent with applicable FDA restrictions on charging for investigational devices and avoiding premature commercialization.

Contracts and Payment Flows Should Match the Operating Model

The sponsor should identify which entity signs site and CRO agreements, approves budgets, pays investigators and vendors, imports and owns devices, establishes charges, and bears study risk.

Service fees, payroll, contractor payments, reimbursements, and payments to U.S. or foreign providers may create withholding, reporting, registration or transfer-pricing questions. A treaty may limit federal taxation but does not generally resolve state tax obligations.

Build the Operational Record Before Study Activity Expands

MDD Options can help establish a controlled U.S. clinical-study distribution model covering importation, depot storage, site shipments, device accountability, reimbursement-linked order flows, returns and documented responsibilities.

By mapping inventory ownership, contracting authority, personnel roles, invoicing, receivables and vendor payments, MDD Options can give the sponsor and its tax advisers the operational facts needed to assess and manage potential U.S. tax presence before study activity expands.